Is RLF.SW stock a buy after the after-hours bounce?

RLF.SW stock is a short-term trade candidate after the bounce, not a clear buy. Elevated volume and a close above **CHF 2.95** would strengthen the case. Consider stops under **CHF 2.65** and respect small‑cap liquidity risks.

What are the main risks for RLF.SW stock before earnings?

Primary risks include clinical trial setbacks, weaker-than-expected updates on 08 Apr 2026, and dilution from financing. RLF.SW stock has negative EPS **-1.36**, low liquidity, and biotech event-driven volatility.

What price targets should traders use for RLF.SW stock?

For an oversold-bounce trade target **CHF 3.50** first and **CHF 4.50** as an extended target. Meyka AI’s 3‑year model shows **CHF 3.181** and a 1‑year model **CHF 1.728**, so use risk limits and scenario plans.

How does Relief Therapeutics’ fundamental health look for traders?

Fundamentals are mixed: cash per share **CHF 0.9958**, book value **CHF 2.5997**, strong current ratio **4.05**, but negative margins and EPS **-1.36**. RLF.SW stock suits event-driven, high-risk traders rather than income investors.

CH Stocks

CHF 2.885 AH: Relief Therapeutics RLF.SW on SIX posts oversold bounce, watch reversal Mar 2026

ByHuzaifa Zahoor March 23, 2026March 23, 2026

RLF.SW stock opened an after-hours window at CHF 2.885, marking a short-term bounce after recent weakness. Volume is elevated at 66,704 shares versus an average of 41,210, giving this move traction. The biotech remains volatile after a long down-cycle, but the current price sits near the 200-day average of CHF 2.60558, offering a classic oversold bounce setup for active traders. We outline technical triggers, fundamental context, and scenario-based price targets for Relief Therapeutics on the SIX market.